Amgen’s Tavneos Crisis: FDA Retraction, Safety Scrutiny, and Market Fallout
Amgen faces FDA and EMA withdrawal of Tavneos after NEJM retraction, with data integrity and liver‑injury concerns highlighted.
6 minutes to read
Dr. Michael Chen
Biotech Science Reporter
Molecular biologist turned biotech journalist with PhD in Genetics and 9 years of experience covering drug discovery, clinical trials, and regulatory approvals. Former research scientist who transitioned to journalism to explain breakthrough therapies and biotechnology innovations. Specializes in gene therapy, immunotherapy, rare disease treatments, and the science behind novel drug mechanisms.
AI Author, more information here
EMA Grants Expanded Approval for Enhertu & Datroway, Boosting AstraZeneca’s Oncology Footprint
Enhertu’s new EMA approval expands AstraZeneca’s HER2‑positive market, while Datroway gains European access, boosting oncology reach and shareholder confidence.
4 minutes to read
Investors Eye Bayer as Glyphosate Legal Risks and Life‑Science Growth Shape Stock Outlook
Explore how Bayer’s share decline reflects legal risks and its life‑science strategy, from oncology breakthroughs to glyphosate litigation impacts.
4 minutes to read
NASP: Sobi’s Nano‑Enzyme Breakthrough for Gout—FDA Response & Future Outlook
NASP, Sobi’s nano‑encapsulated sirolimus‑pegadricase combo, cuts gout uric acid by 2.5 mg/dL with no safety hits—yet FDA demands tighter CMC and CMF controls before approval.
4 minutes to read
How Eli Lilly’s Medicare Weight‑Loss Wins, Centessa Acquisition, and Jaypirca Boosts Stock Rally
Explore how Eli Lilly’s Medicare weight‑loss rollout, Centessa acquisition, and breakthrough oncology drug Jaypirca fuel a rally in defensive healthcare stocks.
3 minutes to read
Takeda Raises ¥1.2 Trillion, Fuels R&D in Oncology, Autoimmune, and Rare Diseases
Takeda raises ¥1.2 trillion to fuel a high‑investment R&D pipeline across oncology, autoimmune, rare disease and neurology, boosting shareholder confidence and market share.
4 minutes to read
Merck’s Biopharma Surge: Resilience, Regenerative Therapies & Investor Confidence in a Value‑Focused Market
Merck’s MRK gains amid market rotation, driven by its cardiometabolic, oncology, vaccine, and cell‑therapy breakthroughs—showing resilience and value for investors.
4 minutes to read
AbbVie’s SKYRIZI Pediatric Approval and Apogee Deal Drive Healthcare Stock Gains
AbbVie’s FDA approval of SKYRIZI® for pediatric psoriasis and psoriatic arthritis, with weight‑based dosing and a new AD candidate, boosts its immunology portfolio and investor appeal.
4 minutes to read
Merck KGaA’s Bio‑Techne Deal Fuels Long‑Term Growth Amid DAX Decline
Merck KGaA’s June 26 market dip masks a strategic gain: a Bio‑Techne acquisition and robust oncology/mRNA pipeline signal long‑term growth amid sector volatility.
3 minutes to read
Amgen Faces FDA Data‑Integrity Probe Over Tavneos Rare‑Disease Therapy
FDA questions Amgen’s Tavneos data integrity for rare liver disease. Discover how regulatory scrutiny, post‑approval evidence, and market impact shape this therapy’s future.
4 minutes to read